---
title: "Amylyx reports clean safety in lowest-dose cohort of Phase 1 LUMINA trial of ALS drug AMX0114"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290551981.md"
description: "Amylyx Pharmaceuticals reported clean safety data from the lowest-dose cohort of its Phase 1 LUMINA trial for ALS drug AMX0114. The early readout showed no drug-related serious safety issues, supporting dose escalation. Biomarker signals remained steady versus baseline, leaving efficacy unclear. The randomized, placebo-controlled study is ongoing in Canada and the US, with higher-dose cohorts underway. Data will be presented at ENCALS 2026."
datetime: "2026-06-23T11:00:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290551981.md)
  - [en](https://longbridge.com/en/news/290551981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290551981.md)
generator: "portal-rs"
---

# Amylyx reports clean safety in lowest-dose cohort of Phase 1 LUMINA trial of ALS drug AMX0114

-   Amylyx flagged first-in-human Phase 1 LUMINA data for AMX0114 in ALS for presentation at ENCALS 2026 on June 24. \* Early readout from the lowest-dose cohort showed no drug-related serious safety issues, supporting escalation to higher doses. \* Biomarker signals held broadly steady versus baseline, leaving efficacy implications unclear at this stage. \* The randomized, placebo-controlled multiple-ascending-dose study is running in Canada and the US, with additional higher-dose cohorts underway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260623249003) on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)

## Related News & Research

- [AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial](https://longbridge.com/en/news/296265581.md)
- [BUZZ-Amylyx dips after increased $500 mln stock sale to fund blood sugar drug](https://longbridge.com/en/news/296483560.md)
- [Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial](https://longbridge.com/en/news/296217967.md)
- [Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M](https://longbridge.com/en/news/296538977.md)
- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**